An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy

T Pillaiyar, M Manickam, V Namasivayam… - Journal of medicinal …, 2016 - ACS Publications
Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that
infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in …

Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban

IY Gong, RB Kim - Canadian Journal of Cardiology, 2013 - Elsevier
Warfarin has been the mainstay oral anticoagulant (OAC) medication prescribed for stroke
prevention in atrial fibrillation (AF) patients. However, warfarin therapy is challenging …

New antiplatelet drugs and new oral anticoagulants

V Koenig-Oberhuber, M Filipovic - BJA: British Journal of …, 2016 - academic.oup.com
In our daily anaesthetic practice, we are confronted with an increasing number of patients
treated with either antiplatelet or anticoagulant agents. During the last decade, changes …

Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study

X Delavenne, P Mismetti, T Basset - Journal of pharmaceutical and …, 2013 - Elsevier
We described the development and full validation of a rapid, high throughput sensible and
accurate LC method using tandem mass spectrometry detection for determining apixaban …

Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage

P Le Roux, CV Pollack, M Milan, A Schaefer - Journal of neurosurgery, 2014 - thejns.org
Patients receiving anticoagulation therapy who present with any type of intracranial
hemorrhage—including subdural hematoma, epidural hematoma, subarachnoid …

The role of prothrombin complex concentrates in reversal of target specific anticoagulants

K Babilonia, T Trujillo - Thrombosis Journal, 2014 - Springer
Over the past several years a new era for patients requiring anticoagulation has arrived. The
approval of new target specific oral anticoagulants offers practitioners several advantages …

Диагностика и коррекция расстройств системы гемостаза

СВ Синьков, ИБ Заболотских, ЕВ Ройтман - 2017 - elibrary.ru
В книге рассмотрены основные положения физиологии системы гемостаза и
диагностики ее нарушений, дана характеристика фармакологических препаратов …

The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

S Rachidi, ES Aldin, C Greenberg, B Sachs… - Expert review of …, 2013 - Taylor & Francis
Venous thromboembolism is a common cause of morbidity and mortality among patients
undergoing elective orthopedic surgery. Due to the high incidence of venous …

Management of venous thromboembolism: recent advances in oral anticoagulation therapy

SW Finks, TC Trujillo… - Annals of …, 2016 - journals.sagepub.com
Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute
treatment of venous thromboembolism (VTE) as well as practical considerations when using …

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins

E Milner, M Ainsworth, M Gleaton… - Journal of Clinical …, 2022 - Wiley Online Library
What is known and objectives Although the apixaban Food and Drug Administration (FDA)
package insert recommends dose reduction in patients administered dual strong inhibitors …